Clinical analysis of 12 cases of acute myeloid leukemia with Ph chromosome and BCR-ABL positive.
- Author:
Xin-Hong FEI
1
;
Shu-Lan WU
;
Rui-Juan SUN
;
Jia-Rui ZHOU
;
Jing-Bo WANG
;
Tong WANG
;
Hong-Xing LIU
;
Hui WANG
;
Chun-Rong TONG
;
Tong WU
;
Dao-Pei LU
Author Information
1. Beijing Dao-Pei Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Child;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
diagnosis;
Male;
Middle Aged;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
Prognosis
- From:
Journal of Experimental Hematology
2012;20(3):545-548
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to analyze the characteristics of morphology, immunology, cytogenetic and molecular biology of leukemia cells in 12 AML patients with Ph(+) and their correlation with survival of patients. 12 patients with Ph(+) AML were diagnosed according to diagnostic criteria of WHO and existence of t(9;22) (q34;q11) or t(9;22) abnormality, meanwhile no evidence of CML chronic phase was observed. The results showed that 8 out of 12 cases were confirmedly diagnosed to be AML by morphologic and immunophenotypic examination, 4 cases were diagnosed as myeloid and B lymphocytic mixed acute leukemia. The Ph chromosome was detected in 10 cases by chromosome analysis at the first time of diagnosis, and some of the cases had coexistence of complex chromosome and/or normal karyotype. BCR-ABL transcript was detected in all 12 cases, including 7 cases with b3a2, 1 case with b2a2, 1 case with b2a2 variants, 2 cases with e1a2 and 1 case with e18a2. The 12 cases all got complete remission after chemotherapy and/or gleevec treatment, out of them 3 cases received chemotherapy and gleevec treatment, but 2 cases died; 9 cases received allogeneic hematopoietic stem-cell transplantation (allo-HSCT), 1 case died from relapse, among them 1 case died from transplant complications. The median survival was 24 (8 - 80) months, the overall survival of 3 years was (51.4 ± 17.7)%. It is concluded that the Ph(+) AML is a acute myelogenous leukemia with poor prognosis, but long-term survival may be achieved with HSCT as quick as after complete remission from gleevec and chemotherapy treatment. Meanwhile, the detection of BCR-ABL gene and it variants may be give more opportunity for diagnose and treatment, which can be used as routine screening for newly diagnosed leukemia.
